D espite currently available drug and device therapies, 25% to 35% of patients with heart failure (HF) and a reduced left ventricular ejection fraction (LVEF) remain categorized in New York Heart Association (NYHA) functional class III (1) . Although these patients are not considered sick enough for advanced invasive HF therapies, such as a left ventricular assist device or heart transplantation, they exhibit moderate to severe HF symptoms, poor quality of life (QoL), and substantial limitation in exercise capacity. They are also at substantial risk for HF morbidity (e.g., HF hospitalization) and mortality, thereby incurring significant health care costs (2) . Thus, there is a need for new therapies that can improve clinical status and outcomes in these patients.
Considerable clinical and experimental evidence supports a major role for activation of the adrenergic nervous system and parasympathetic nervous system withdrawal in the genesis of HF symptoms and in HF disease progression (3, 4) . This autonomic imbalance exerts adverse effects on the heart, blood vessels, and kidneys, resulting in pathological left ventricular remodeling, peripheral vasoconstriction, and salt and water retention, respectively. These observations, along with the success of adrenergic receptor blockade in the treatment of HF, provide a rationale for therapies that inhibit adrenergic activity, enhance parasympathetic activity, or, preferably, accomplish both (5, 6) . Such therapies should ideally produce natural physiological autonomic adaptation, as a trial of total pharmacological adrenergic blockade with moxonidine worsened, rather than improved, clinical outcomes (7) .
One such therapy that has shown promise in preliminary human studies of HF is baroreflex activation therapy (BAT), an electrical stimulation technology delivered by an implanted device resembling a cardiac pacemaker (8, 9) . Stimulation of the carotid baroreceptor with BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity, resulting in increased arterial and venous compliance and reduced peripheral resistance. In patients with resistant hypertension, BAT has been shown to be safe and effective for lowering excessive blood pressure (BP) (9) . In patients with HF, a small, single-center, open-label study demonstrated safety, a significant and sustained 30% reduction in sympathetic nerve activity measured directly by peroneal nerve microneurography, and improvement in HF clinical status assessed by changes in NYHA functional class, QoL score, and 6-min hall walk (6MHW) distance (10) . Cardiac structure and function, assessed by 3-dimensional echocardiography, also improved. The rate of HF hospitalization was also substantially decreased compared with the 12 months before implantation of the BAT system.
We report the results of a multinational, prospective, randomized, parallel-controlled, clinical trial of BAT in HF, performed to confirm and extend these findings. Because of varying regulatory requirements, the protocol for each country was slightly different, but major eligibility criteria and endpoints were harmonized. Patients provided their written informed consent before enrollment. Patients randomized to receive BAT were implanted with the BAT system, as previously described. If a preexisting cardiac rhythm management device was present, interaction testing was conducted to confirm unimpeded performance of the systems (14) . BAT was initiated either before discharge or within 2 weeks after discharge. Mandatory follow-up visits for patients receiving BAT occurred at 2 weeks and at 1, 2, 3, were assigned to the control group and 76 (40 US and 36 OUS) were assigned to BAT. One patient in the control group died before the activation date, and 5 patients in the treatment group withdrew consent or were withdrawn by the site before system implantation and their activation dates. The 2 groups were similar with respect to baseline characteristics, except for a significantly worse QoL score in the treatment group, a significantly higher rate of diuretic agent use in the treatment group, and a trend toward a higher rate of HF hospitalization before enrollment in the treatment group ( Table 1) . The effect of BAT on the rate of HF hospitalization and on the mean number of days hospitalized for HF is summarized in Table 3 . During the 6 months before enrollment, there was an apparent difference 
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The disposition of patients is shown in
DISCUSSION
The results of the present study indicate that BAT is safe and significantly improves NYHA functional class, QoL, and exercise capacity in patients with NYHA functional class III HF with reduced LVEFs.
The magnitude of these benefits was similar to, if not greater than, that reported with currently available effective drug and device therapies for HF, and yet they were seen in patients already receiving these therapies (15, 16) . These results corroborate the See text for details.
FIGURE 2 Effect of BAT on BP
Baroreflex activation therapy (BAT) significantly increased systolic blood pressure (BP) (A) and pulse pressure (B), with no effect on diastolic BP. In contrast, there were trends toward decreasing systolic BP and pulse pressure in the control group. DBP ¼ diastolic blood pressure;
Med Mgmt ¼ medical management; PP ¼ pulse pressure; SBP ¼ systolic blood pressure. STUDY LIMITATIONS. The relatively small number of patients studied may limit the interpretation of some of the results of the present study. Another potential limitation may be the lack of patient blinding and a sham control, leading to a "placebo effect" in the treatment arm, or a lack of blinding in investigator assessment of end points, leading to bias. However, the magnitude of improvement in the primary end points is substantially larger than that attributable to such a placebo effect or bias in prior device trials. For example, in prior studies of CRT, the implantation of an inactive device was associated with a 10-m improvement in 6MHW distance (15) , a placebo effect that falls far short of the nearly 60-m improvement seen with BAT in the present study. In addition, at least 1 of the end points significantly improved by BAT, NT-proBNP, is not prone to a placebo effect. The difference in follow-up schedule between study groups OUS has the potential to bias the results.
However, there were no statistically significant differences in the treatment effect between the US and OUS subjects. Similarly, the differential collection of hospitalization data by world region could also introduce bias. However, data presented in Table 3 indicate similar hospitalization trends in both major geographies of the study.
Our study results are strengthened by a high standard of baseline pharmacologic and device-based therapy (87% ICD, 32% CRT). For comparison, in a recently published HF drug trial, only 15% of patients received ICDs and 7% received CRT devices, despite a quite similar ejection fraction boundary for inclusion (19) . Hence, our results indicate that HF therapy can be improved in an already very well treated, but very symptomatic HF population.
CONCLUSIONS
In summary, BAT is safe and significantly improves functional status, QoL, exercise capacity, and NT-proBNP in well-treated patients with NYHA functional class III HF. The data also support the possibly that BAT reduces the rate of HF hospitalization and the number of days hospitalized for HF.
This latter observation should be confirmed in an adequately powered prospective outcome trial.
